<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Feres, Fausto</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">No Change in Thrombotic Risk with Short-Term DAPT after Stenting</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-21</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents the final results from the Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice trial [OPTIMIZE; Feres F et al. JAMA 2013], demonstrating that in patients with coronary heart disease who received a drug-eluting stent (DES), cessation of dual antiplatelet therapy 3 or 12 months after implantation did not increase their risk of the composite endpoint of death, myocardial infarction, stroke or major bleeding, or stent thrombosis at 1-year follow-up.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>